Suzhou Ribo Life Science Co., Ltd. (6938)

Overview

Suzhou Ribo Life Science Co., Ltd. is a prominent biotechnology firm focused on the research, development, and industrialization of small nucleic acid drugs, prominently leveraging RNA interference (RNAi) technology and oligonucleotide therapeutics. The company is dedicated to addressing cardiovascular, metabolic, renal, liver, and various other chronic diseases through a comprehensive and vertically integrated platform that spans the entire lifecycle of drug development—from initial research and development to commercialization. This includes the use of proprietary technologies, such as the liver-targeted delivery platform RiboGalSTAR and innovative chemical modification systems.

Founded in 2007 and headquartered in Kunshan, China, Suzhou Ribo Life Science Co., Ltd. is committed to pioneering oligonucleotide drugs to meet significant medical needs in the realm of chronic disease management. The company is advancing a robust pipeline of siRNA drug candidates, targeting a variety of health conditions including thrombotic diseases, hypertriglyceridemia, hypercholesterolemia, hepatitis, and renal disorders. Several of these candidates are currently in clinical development phases, including Phase II and Phase I trials. The company operates R&D centers in Beijing and Suzhou, and maintains an international presence in Gothenburg, Sweden, which supports its global clinical development strategy and partnerships with renowned multinational pharmaceutical companies.

Products and Services

• RNA Interference (RNAi) Therapeutics

  Utilizing RNAi technology, Suzhou Ribo develops innovative therapies aimed at silencing specific genes associated with various diseases. This approach holds great potential for treating chronic conditions by effectively regulating gene expression and mitigating pathological processes.

• Oligonucleotide Therapeutics

  The company specializes in the design and production of oligonucleotides, which are short DNA or RNA molecules used to treat genetic disorders or diseases by targeting specific molecular pathways to restore normal function.

• Pipeline Development of siRNA Candidates

  Suzhou Ribo Life Science is advancing a diverse pipeline of small interfering RNA (siRNA) drug candidates, which are in various stages of clinical trials. These candidates include treatments for conditions like thrombotic diseases, hypertriglyceridemia, hypercholesterolemia, hepatitis, and renal disorders.

• Proprietary Delivery Platforms

  The RiboGalSTAR platform enables targeted delivery of oligonucleotide drugs specifically to the liver, enhancing the efficiency and efficacy of treatment while potentially reducing side effects.

• Chemical Modification Systems

  This service involves the modification of oligonucleotides to improve their stability, reduce immunogenicity, and enhance their pharmacokinetic properties, thus optimizing therapeutic outcomes.

• Research and Development Collaboration

  Suzhou Ribo Life Science actively engages in partnerships with multinational pharmaceutical companies, fostering collaborative research efforts to accelerate the development of new therapeutics and expand its reach into global markets.

• Clinical Development Support

  The company offers comprehensive support for global clinical development initiatives, including regulatory guidance, clinical trial management, and data analysis, ensuring a streamlined process from research to market launch.